incanthera



Innovative Products for Dermatology and Oncology

AGM 2025

Disclaimer

- The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Incanthera plc (the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.
- This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and you own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.
- No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.
- This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are subject to updating, completion, revision, further verification and amendment without notice.
- Past performance is not a guide to future performance.
- Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship.
- The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.
- This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.
- By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.

Incanthera plc

- Incanthera is a specialist company dedicated to innovative technologies in dermatology and oncology.
- Established in 2010 as a spin out from the Institute of Cancer Therapeutics, University of Bradford.
- Listed UK Aquis Stock Exchange (INC:AQSE), Feb 2020
- Incanthera's recent focus has been on dermatological delivery technology and formulations.
- On 11 August 2025, Incanthera launched a unique luxury skincare brand Skin+CELL to the global marketplace, through a Direct To Consumer (DTC) campaign.



Skin+CELL: Testimonials

“10/10. Brilliant product - really improved my skin. Wonderful smell. This Summer I trialed this product. I thoroughly enjoyed using it. The consistency was perfect. Thick and rich but not sticky. My face felt replenished and moisturised. The smell was wonderful, and the improvement was noticeable. I LOVED IT! ”

S.

‘I recently purchased the face cream and used it on lesions on my head, I am looking to purchase another as it has made visible improvements.”

Anonymous.

Skin + Cell is by far the best hand cream I have ever used. Soft and non greasy, it feels like silk when you apply it. I am looking forward to using the other products in the range and hope there will be an SPF face cream soon. The niacinamide can help build proteins in the skin and lock in moisture to prevent damage, keeping the skin firm and healthy over the long term.

Sarah, Pharmacist UK

Omg I love the Skin+Cell cream!!! Plus a little goes a long way. Still using the first sample and I am off on a flight so will take with me to test at altitude. I am over the moon because as I have got older I’ve been searching for a cream that I feel will seriously deliver results and last me for a long time Xxx

54 year old, Tracey G

I have had acne for 5 years which has massively affected my self esteem. I have loved using this cream, my skin feels normal again & non greasy. Please get this on Tiktok

20 year old, Charlie



DTC Campaign to date

- Skin+CELL; establishing a new brand
- There has been immediate positive feedback from users of our Skin+CELL products
- SALES: achieved across product range, multiple hits across all the media platforms, valuable proprietary data and purchasing habits
- As the DTC campaign has developed, we have better insight of our market, enabling us to focus the marketing campaign
- We are creating an advisory group
    - DTC beauty/branding, pricing e-commerce/industry experts



Looking Forward

- Active discussions ongoing to establish multiple routes to global markets for Skin + CELL through
  - DTC
  - Retail/Wholesale
  - Territorial Licensing
  - Collaboration with global high-profile celebrities
- Introducing new products with different active ingredients utilising the unique delivery system, including a suncare range (currently in development)
- Licence our technologies to commercial partners to develop their own skincare products under their own branding.
- Pursue selective pharmaceutical development